Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220155 | 0.85 | DAO (0.66) | DAOLMNAPDE2APDE3BPDE3A | |
| SCHEMBL7359339 | 0.81 | GRIA1 (0.57) | DAOLMNAPDE2APDE3BPDE3A | |
| SCHEMBL15344980 | 0.80 | MAPT (0.52) | DAOLMNAPDE2APDE3BPDE3A | |
| SCHEMBL3066593 | 0.79 | LMNA (0.57) | DAOLMNAMAPTMAOBPGR | |
| SCHEMBL194166 | 0.79 | DAO (0.64) | DAOLMNAMAPTMAOBTP53 | |
| SCHEMBL25318060 | 0.79 | LMNA (0.56) | DAOLMNAMAPTMAOBTP53 | |
| SCHEMBL625508 | 0.79 | MAPT (0.59) | DAOLMNAMAPTMAOBTP53 | |
| SCHEMBL31192592 | 0.79 | DAO (0.64) | DAOLMNAMAPTMAOBTP53 | |
| SCHEMBL1639030 | 0.79 | LMNA (0.56) | DAOLMNAPDE2APDE3BPDE3A | |
| SCHEMBL31053821 | 0.79 | LMNA (0.56) | DAOLMNAPDE2APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200306257-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2020-10-01 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019060365-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2010015037-A1 | THERAPEUTIC METHODS AND COMPOSITIONS | HOWARD FLOREY INSTITUTE (AU) | 2010-02-11 | — | — | WO | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009034029-A2 | 1-SUBSTITUTED 4-HETEROCYCLYLPIPERIDINES FOR USE AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5391566-A | An endothelin antagonist, hypotensive agents, antiinflammatory agents for treating cardiovascular disorders, kidney disorders , brain disorders, asthma | MERCK & CO., INC. (US) | 1995-02-21 | — | — | US | disclosed |
| WO-1995003044-A1 | BENZIMIDAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306257-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | DAO 1975/4885LMNA 1766/4885PDE2A 1160/4885 |
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | DAO 3505/4885LMNA 4848/4885PDE2A 1457/4885 |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | MAP3K20, MAP3K1, PACSIN2 | DAO 1975/4885LMNA 1766/4885PDE2A 1160/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | DAO 537/4885LMNA 4065/4885PDE2A 609/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | DAO 1764/4885LMNA 3892/4885PDE2A 1405/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | DAO 1503/4885LMNA 731/4885PDE2A 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.